JPMorgan Chase & Co. Sells 53,460 Shares of Doximity, Inc. (NASDAQ:DOCS)

JPMorgan Chase & Co. lowered its holdings in Doximity, Inc. (NASDAQ:DOCS) by 10.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 444,596 shares of the company’s stock after selling 53,460 shares during the period. JPMorgan Chase & Co.’s holdings in Doximity were worth $23,737,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Global Retirement Partners LLC lifted its position in Doximity by 468.1% during the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock worth $29,000 after buying an additional 440 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Doximity by 69.1% during the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock worth $31,000 after purchasing an additional 235 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Doximity by 49.4% during the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock valued at $40,000 after purchasing an additional 250 shares during the last quarter. Optimum Investment Advisors acquired a new stake in shares of Doximity in the fourth quarter valued at approximately $43,000. Finally, Morse Asset Management Inc bought a new position in Doximity in the 3rd quarter worth approximately $46,000. Institutional investors own 87.19% of the company’s stock.

Insider Buying and Selling

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 37.40% of the stock is owned by company insiders.

Doximity Price Performance

Shares of Doximity stock opened at $55.59 on Thursday. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $85.21. The company has a market capitalization of $10.38 billion, a P/E ratio of 55.59, a price-to-earnings-growth ratio of 4.10 and a beta of 1.41. The business has a 50-day moving average of $65.02 and a two-hundred day moving average of $55.34.

Wall Street Analysts Forecast Growth

DOCS has been the topic of a number of recent research reports. Bank of America increased their price objective on Doximity from $54.00 to $57.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Canaccord Genuity Group raised their price target on Doximity from $60.00 to $71.00 and gave the company a “hold” rating in a report on Friday, February 7th. Leerink Partnrs raised shares of Doximity from a “hold” rating to a “strong-buy” rating in a research note on Friday, February 7th. Piper Sandler upgraded shares of Doximity from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $31.00 to $78.00 in a research report on Friday, February 7th. Finally, Raymond James restated an “outperform” rating and issued a $83.00 price objective (up from $65.00) on shares of Doximity in a report on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $64.22.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.